VWM
CPRX

Venturi Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Venturi Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-215
Closed -$4.49K – 832
2024
Q4 		$4.49K Hold
215
– – ﹤0.01% 1713
2024
Q3 		$4.28K Buy
+215
New +$3.99K ﹤0.01% 1514
2024
Q1 		– Sell
-1,000
Closed -$16.8K – 1378
2023
Q4 		$16.8K Hold
1,000
– – ﹤0.01% 748
2023
Q3 		$11.7K Hold
1,000
– – ﹤0.01% 769
2023
Q2 		$13.4K Buy
+1,000
New +$14.4K ﹤0.01% 615

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Venturi Wealth Management's CPRX Position: Q1 2025 in Review

Venturi Wealth Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2025, closing a stake of 215 shares — an estimated $4.49K sold.

Venturi Wealth Management first reported a position in CPRX in Q2 2023 and held it in 5 quarters. The position peaked at $16.8K in Q4 2023. 371 funds tracked by Wall St. Rank hold CPRX as of Q1 2025.

  • Venturi Wealth Management reported no remaining Catalyst Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Venturi Wealth Management sold 215 Catalyst Pharmaceutical shares in Q1 2025, an estimated $4.49K.
  • Venturi Wealth Management first reported a position in Catalyst Pharmaceutical in Q2 2023 and held it in 5 quarters.
  • Venturi Wealth Management's Catalyst Pharmaceutical position peaked at $16.8K in Q4 2023.
  • 371 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2025.

Based on Venturi Wealth Management's 13F filing for Q1 2025, filed 6 May 2025.